German digital medtech startup hema.to receives €3.6 million investment from LUMO Labs and Bayern Kapital for AI-based blood data analysis.

Eindhoven, February 27th, 2025 – Munich-based digital medtech company hema.to today announced the successful closing of a new €3.6 million funding round led by LUMO Labs and followed byBayern Kapital, several US angel investors, and investors from their previous round. Hema.to automates complex blood data analysis through AI-powered cytometry, reducing lab analysis time from ~20 minutes to 1 minute, eliminating human subjectivity in detecting leukaemia and lymphoma, and eradicating 90% of false negatives for secondary pathologies.

Hema.to’s AI pulls data from a massive database of over 600,000 files from over 20 leading centers. With their CE-marked AI models for clinical-grade performance and their new end-to-end solution in the process of a new certification, Hema.to is already helping labs and hospitals across Europe diagnose blood cancers.

The newly raised funds will be used to refine product-market-fit in their first segment of blood cancer diagnostics, including additional European certification, and for clinical studies, expansion into diagnosis of broader immune disorders, and scaling commercial deployment.

“At hema.to we like to say that we want to ‘make your blood speak’”, says Karsten Miermans, hema.to’s CEO and co-founder. “Every 3rd person suffers from a life-altering immune disease at some point in their life. Blood data holds the key to the immune system, but at present life-threatening illnesses like leukaemia or lymphoma, can be overlooked in blood analysis—even when the data that indicates otherwise is right there. Through the AI models on our platform, we pull this data to the surface to get every patient an accurate diagnosis and treatment as early as possible. This is how we save lives.”

Amidst rising sample volumes and workforce shortages in Europe’s busiest clinical labs, cytometry teams typically need 20 minutes per patient sample, concentrating on complex, high-dimensional blood data. Fatigue, rising workloads, and limited staffing add to the risk of missed or delayed diagnosis.

“Through our investments in emerging technologies in Digital Health and Medtech, we want to improve the quality of life of patients and professionals and relieve the ever-increasing strain on public healthcare”, saysSven Bakkes, Founding Partner of LUMO Labs. “We are very happy to welcome hema.to into our portfolio. Their AI-powered platform scans raw cytometry files in seconds, detecting more diseases than human analysts can and soon also at earlier stages. For busy clinicians, that means a fraction of the manual analysis time. For patients, it can be the difference between a missed pathology and a life-saving early intervention.”

Hema.to is headquartered in Munich and has 22 full-time employees across Germany, Portugal, Spain, Poland and Belgium.

In addition to the commercial deployment of their CE-marked AI engine in Europe, hema.to has academic collaborations in the US top-ranking institutes such as U Penn, and a distribution partnership in Israel.

“The workload and pressure in clinical laboratories is high and for life-threatening diseases such as leukemia or lymphoma, early and accurate diagnosis can make the difference between negative disease progression and life-saving, early intervention. With hema.to‘s AI-supported analysis platform, the time taken to analyze blood data can be reduced to a fraction of the usual manual time. In this way, the company not only relieves the burden on clinical laboratories and promotes patient well-being, but also addresses a global market with a volume of several billion dollars. We therefore see great potential in hema.to‘s solution – both in Europe, where it is already being used in various laboratories and internationally,” says Monika Steger, Managing Director of Bayern Kapital.